ArticleCancer medicine2023

Matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma.

Joshua Richter et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.